Evidence map›Paper›PMID 40618316›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Development of a CYP11B2 imaging tracer for primary aldosteronism: basic evaluation of iodine- and fluorine-incorporated pyridinyldihydroquinolinone derivatives.

Yusuke Yagi, Hiroyuki Kimura, Riko Fuseda, Takaaki Murakami, Marina Omokawa, Kaito Ohta, Satoko Kise, Masakatsu Sone, Hiroyuki Yasui, Nobuya Inagaki and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yusuke YagiDepartment of Radiological Technology, Faculty of Medicinal Science, Kyoto University of Medical Science, 1-3 Imakita, Oyama-higashi, Sonobe, Nantan, Kyoto, 622-0022, Japan.
Hiroyuki KimuraAgency for Health, Safety and Environment, Kyoto University, Yoshida-konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. kimura.hiroyuki.4u@kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-4291-3524
Riko FusedaLaboratory of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Sciences, Kyoto Pharmaceutical University, 5 Nakauchi-choYamashina-ku, MisasagiKyoto, 607-8414, Japan.
Takaaki MurakamiDepartment of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University Hospital, 54 Shogoin-kawaharaawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Marina OmokawaFaculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Kaito OhtaDivision of Probe Chemistry for Disease Analysis/Central Institute for Radioisotope Science, Research Center for Experimental Modeling of Human Disease, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.
Satoko KiseDivision of Probe Chemistry for Disease Analysis/Central Institute for Radioisotope Science, Research Center for Experimental Modeling of Human Disease, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.
Masakatsu SoneDepartment of Metabolism and Endocrinology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan.
Hiroyuki YasuiLaboratory of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Sciences, Kyoto Pharmaceutical University, 5 Nakauchi-choYamashina-ku, MisasagiKyoto, 607-8414, Japan.
Nobuya InagakiDepartment of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University Hospital, 54 Shogoin-kawaharaawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
Hideo SajiDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida-shimohimo-adachidachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan. saji.hideo.l70@kyoto-u.jp.

Funding

Japan Agency for Medical Research and Development A134Japan Society for the Promotion of Science JP18K15566Japan Society for the Promotion of Science JP20K08061Japan Society for the Promotion of Science JP22K15852
6 · The paper itself

Abstract

backgroundCurrent methods for diagnosing primary aldosteronism (PA) are limited by their invasiveness and diagnostic accuracy. This study aimed to develop nuclear medicine imaging tracers targeting CYP11B2, which is overexpressed in patients with PA.

resultsWe successfully synthesized iodinated and fluoroethoxynated pyridinyldihydroquinolinone (PDHQ) derivatives, among which PDHQ-1 exhibited the highest selectivity for CYP11B2. Furthermore, [

conclusionsCollectively, our results suggest that [

Indexed as

125IPositron emission tomographyPrimary aldosteronismSingle photon emission tomographyTetrahydropyridoquinolinone

Identifiers

PMID40618316
PMCPMC12229973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.